David Hallett, an experienced biotech executive, has joined Exscientia Ltd as chief operating officer and head of drug discovery. He will be responsible for the company’s work in drug discovery using artificial intelligence technology. Dr Hallett was previously head of alliance management at Evotec SE which is an investor in Exscientia. He trained as a medicinal chemist at Merck & Co Inc, progressing to research fellow and leading teams developing preclinical drug candidates in psychiatry.
Exscientia announced the appointment on 21 January 2020.
Copyright 2020 Evernow Publishing Ltd.